glp 1 constipation and diarrhea Adverse effects of GLP-1 class drugs. Gastrointestinal issues are Real Talk: What You Need

According to statistics, there are currently approximately 50 million people living with AD worldwide, and this number is expected to increase to 152 million by 2050 as the population ages, making it a major challenge for global public health ( The glucagon-like peptide-1 receptor (GLP-1R) is a key target for diabetes mellitus (DM) treatment, and GLP-1R agonists are pharmaceutical compounds employed in the treatment of DM

Because semaglutide slows down digestion, jumping straight to a high dose could cause significant discomfort, such as nausea or stomach upset

So its been going on for a while

As demonstrated by oxyntomodulin, a weak endogenous agonist for GLP-1 receptor and glucagon receptor, a strategy that simultaneously stimulates both GLP-1 and glucagon receptors can reduce food intake while increasing energy expenditure, synergistically enhancing weight loss [105-107]

We have to consider GLP-1 drugs longer-term societal impact because they have the potential to be cost-effective years or decades down the line

The framing is aspirational rather than clinical, positioning pharmacology as status